Maternal and Neonatal Outcomes in Intrahepatic Cholestasis of Pregnancy

The aims of our study were to evaluate the maternal and fetal outcomes of intrahepatic cholestasis of pregnancy (ICP). In this observational, retrospective case–control study, we included all pregnant women who gave birth with a diagnosis of ICP between January 2010 and December 2020 at the Unit of Obstetrics and Gynecology, University Hospital of Messina. The data were compared with those from a control group of pregnant women who did not have ICP. One hundred twenty-nine and eighty-five patients were included, respectively, in the study and in the control group. There was a significant difference between the two groups in the incidence of hypothyroidism, thrombophilia, gestational diabetes, gestational hypertension, postpartum hemorrhage, and preterm delivery, which were more frequent in the ICP patients. No neonatal adverse events were recorded, although a significant difference in the meconium-stained amniotic fluid condition was noted. After a 24-month follow-up, 48/129 patients with ICP accepted to be reassessed by liver ultrasound, elastographic examination, and liver function blood tests. No patient showed signs of chronic liver disease. This study confirmed a higher probability of adverse short-term maternal outcomes in ICP pregnant patients, but a lower probability of adverse short-term fetal outcomes and the absence of a long-term maternal risk of chronic liver disease.

[1]  J. Girling,et al.  Intrahepatic cholestasis of pregnancy , 2022, BJOG : an international journal of obstetrics and gynaecology.

[2]  S. Kane,et al.  Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis , 2021, The lancet. Gastroenterology & hepatology.

[3]  Richard H. Lee,et al.  Society for Maternal-Fetal Medicine (SMFM) Consult Series #53: Intrahepatic Cholestasis of Pregnancy. , 2020, American journal of obstetrics and gynecology.

[4]  W. Jelski,et al.  Intrahepatic Cholestasis in Pregnancy: Review of the Literature , 2020, Journal of clinical medicine.

[5]  U. Beuers,et al.  Ursodeoxycholic acid in pregnancy ? , 2019, Journal of hepatology.

[6]  T. Kawakita,et al.  Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses , 2019, The Lancet.

[7]  Jie Zhou,et al.  Is It Necessary to Perform the Pharmacological Interventions for Intrahepatic Cholestasis of Pregnancy? A Bayesian Network Meta-Analysis , 2018, Clinical Drug Investigation.

[8]  G. Stoddard,et al.  Perinatal outcomes associated with intrahepatic cholestasis of pregnancy* , 2018, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[9]  N. Chen,et al.  Ursodeoxycholic acid protects interstitial Cajal-like cells in the gallbladder from undergoing apoptosis by inhibiting TNF-α expression , 2018, Acta Pharmacologica Sinica.

[10]  E. Livingston,et al.  Intrahepatic Cholestasis of Pregnancy: A Review of Diagnosis and Management. , 2018, Obstetrical & gynecological survey.

[11]  Yong Zhong,et al.  Bile acid levels and risk of adverse perinatal outcomes in intrahepatic cholestasis of pregnancy: A meta‐analysis , 2017, The journal of obstetrics and gynaecology research.

[12]  X. Kong,et al.  Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy , 2016, Medicine.

[13]  Yayi Hu,et al.  Intrahepatic Cholestasis of Pregnancy in Women With Twin Pregnancy , 2016, Twin Research and Human Genetics.

[14]  Joseph C. Ahn,et al.  ACG Clinical Guideline: Liver Disease and Pregnancy , 2016, The American Journal of Gastroenterology.

[15]  Yvonne W. Cheng,et al.  Intrahepatic cholestasis of pregnancy and timing of delivery , 2015, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[16]  C. Henderson,et al.  The risk of infant and fetal death by each additional week of expectant management in intrahepatic cholestasis of pregnancy by gestational age. , 2015, American journal of obstetrics and gynecology.

[17]  T. Kawakita,et al.  Predictors of adverse neonatal outcomes in intrahepatic cholestasis of pregnancy. , 2015, American journal of obstetrics and gynecology.

[18]  J. Marin,et al.  Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the mother-placenta-foetus trio during cholestasis of pregnancy. , 2015, British journal of clinical pharmacology.

[19]  Reena Shah,et al.  Primum non nocere: how active management became modus operandi for intrahepatic cholestasis of pregnancy. , 2014, American journal of obstetrics and gynecology.

[20]  Madeleine Durand,et al.  The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: a meta-analysis including non-randomized studies. , 2014, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[21]  V. Geenes,et al.  Intrahepatic Cholestasis of Pregnancy , 2014, Obstetrics and gynecology.

[22]  C. Raker,et al.  Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. , 2014, European journal of obstetrics, gynecology, and reproductive biology.

[23]  P. Seed,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Association of Severe Intrahepatic Cholestasis of Pregnancy With Adverse Pregnancy Outcomes: A Prospective Population-Based Case-Control Study , 2014 .

[24]  F. Lammert,et al.  A Comprehensive Analysis of Common Genetic Variation Around Six Candidate Loci for Intrahepatic Cholestasis of Pregnancy , 2013, The American Journal of Gastroenterology.

[25]  J. Ludvigsson,et al.  Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: A population‐based cohort study , 2013, Hepatology.

[26]  J. Ludvigsson,et al.  Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12‐year population‐based cohort study , 2013, BJOG : an international journal of obstetrics and gynaecology.

[27]  David A. Miller,et al.  Sudden Fetal Death in Intrahepatic Cholestasis of Pregnancy , 2009, Obstetrics and gynecology.

[28]  J. Marin,et al.  Molecular pathogenesis of intrahepatic cholestasis of pregnancy , 2008, Expert Reviews in Molecular Medicine.

[29]  P. Meier,et al.  Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. , 2008, World journal of gastroenterology.

[30]  S. Lorente,et al.  [Cholestasis of pregnancy]. , 2007, Gastroenterologia y hepatologia.

[31]  F. Lammert,et al.  Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. , 2007, Gastroenterology.

[32]  T. Goodwin,et al.  The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population , 2006, Journal of Perinatology.

[33]  L. Marpeau,et al.  Fetal Death in a Patient With Intrahepatic Cholestasis of Pregnancy , 2006, Obstetrics and gynecology.

[34]  S. Taylor-Robinson,et al.  ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy , 2005, Gut.

[35]  L. Mattsson,et al.  Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates , 2004, Hepatology.

[36]  A. Germain,et al.  Bile acids increase response and expression of human myometrial oxytocin receptor. , 2003, American journal of obstetrics and gynecology.

[37]  P. Meier,et al.  Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. , 2003, Biochimica et biophysica acta.

[38]  Y. Korchev,et al.  The bile acid taurocholate impairs rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis. , 2001, Clinical science.

[39]  S. Heinonen,et al.  Pregnancy outcome with intrahepatic cholestasis. , 1999, Obstetrics and gynecology.

[40]  M. Hadchouel,et al.  Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy , 1999, The Lancet.

[41]  W. Sepulveda,et al.  Vasoconstrictive effect of bile acids on isolated human placental chorionic veins. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[42]  A. Bogte,et al.  Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. , 2015, American journal of obstetrics and gynecology.